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that could be included in a comprehensive measurement
set, falling into the four major categories of PBM activities,
are suggested. CONCLUSIONS: A standardized, compre-
hensive set of performance indicators should be developed
to enable public and private sector purchasing organiza-
tions to evaluate PBM services and the impact of these
activities on quality of care and consumer satisfaction.
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OBJECTIVES: Poland is the next European country,
which is in the process of drafting country-specific guide-
lines for economic evaluation of pharmaceuticals. The
aim of the study was to compare Polish pharmacoeco-
nomic guidelines with international health economic
guidelines, highlighting areas of agreement and dissent.
METHODS: Existing documents from 18 countries were
reviewed, analyzed and a comparison was undertaken.
The following topics were considered: objective, use of
pharmacoeconomic analyses, responsibility in their con-
duct and target audience, methodology and ethical code
of practice while conducting and publishing results of
pharmacoeconomic analysis. The explanation of differ-
ences was taken. RESULTS: For a number of issues rec-
ommendations are consistent between Poland and other
countries. For the purpose of the Polish pharmacoeco-
nomic research guidelines, the Canadian, Australian,
Dutch and Belgian guidelines have, in some parts, been
specially adopted to the Polish situation. In some parts it
was possible to combine certain aspects; in the other, due
to the unique local circumstances, there was a need to de-
velop the methodological guidelines on a pure national
level. For example there is a lack of consensus concerning
costing and utility measurement. CONCLUSIONS: The
guidelines for conducting pharmacoeconomic evaluations
are linked to existing health care system and approaches
to the pricing and reimbursement of pharmaceuticals.
This is the purpose of differences between international
health economic guidelines. To reach an optimal degree
of the use of pharmacoeconomic studies in decision-mak-
ing process it is essential to take into account local situa-
tion and create country-specific guidelines.
PHP6
ACTIVITIES, FUNCTIONS AND STRUCTURE OF 
PHARMACY AND THERAPEUTICS COMMITTEES 
IN ISRAELI HOSPITALS
Rotem R1, Reuveni H2, Goldberg A2
1Sokoka Meidcal Centre, Beer-Sheba, Israel; 2Ben-Gurion 
University, Beer-Sheba, Israel
OBJECTIVES: The pharmacoeconomic litrature shows
that one of the means available to HMOs for wisely us-
ing the medical budget is the Pharmacy and Therapeutics
Committee (PTC). The present procedure for the hospital
PTCs was written by the Ministry of Health in 1978. The
aim of the study was to investigate the Israeli hospitals
PTCs work. METHODS: This study was based upon a
questionnarire which included subjects from the PTCs
procedure and also subjects that the PTC dealt with in
the late nineties. The questionnarire was sent in October
1999 to 51 hospitals. The information was processed on
Excel software. RESULTS: Hospital responses were 41/
51 (80.4%). Thirty one hospitals reported having PTC
and answered the questionnaire, ten hospitals reported
not-having PTC at all. The PTCs chairperson appointed
is a department director as demanded by the Ministry
Procedure by 12 (41%) of the hospitals, the deputy chair-
person nomination matched by 2 (7%) hospitals, orga-
nizer of the PTC nomination matched by 20 (69%) of the
hospitals. The attending doctors specialities are: intern,
pediatrics, surgery, gynecology, infection diseases, anes-
thesiology and mental health. Nine (31%) hospitals re-
ported having a PTC procedure, 28 (97%) hospitals are
checking requests for enlarging the local formulary and
just 25 (86%) recommend of formulary reduction; 20
(69%) hospital PTCs recommended 50 guidelines to the
local management and 28 of them were addopted. CON-
CLUSION: From the returned questionaries it seems that
no PTC keeps the entire procedure. In 1999, the local
PTCs reported adding 494 medicines and decreasing 48,
which means a total of 446 medicines added. One hun-
dred seventy nine members of PTCs formed 50 guide-
lines; 28 of them were accepted by the local management.
There is no control of the Ministry of Health on the PTCs
procedures implementation; the procedure has not been
upgraded since 1978 and it is not familiar to most of the
hospitals.
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OBJECTIVES: The field of health economics (HE) has
undergone vast growth over the last decade. One contin-
ually evolving main factor is the motivation for perform-
ing HE studies, in particular in Canada because of chang-
ing requirements for provincial formulary submissions.
The objective of this study was to determine how HE
data is being applied by the Canadian pharmaceutical in-
dustry to date. METHODS: A survey was sent to key
personnel working in HE in the Canadian pharmaceuti-
cal industry and followed-up. Data from returned surveys
were compiled in a database, tabulated, and evaluated.
RESULTS: Twenty-one (84%) of 25 surveys sent to com-
panies reporting previous experience with HE were re-
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turned; 90% of these companies were firms with more
than 100 full-time employees. Of the respondents, 67%
currently have a department or unit whose sole responsi-
bility is HE, up from 12% reported in a previous study
for 1995. The application of HE information by Cana-
dian pharmaceutical companies is most often for provin-
cial formulary submissions (100%), marketing (86%)
and pricing (81%). It is also used by 62% of respondents
for internal training and medical education programs.
Relatively few Canadian companies apply HE informa-
tion to managed care decision-making (38%) and patient
education (24%). Health economic research data was
published by 3/4 of the respondents in the form of scien-
tific posters or conference presentations and by 2/3 in the
biomedical, peer-reviewed literature. Ninety percent of
respondents cited plans for new HE studies in Canada
within the next year. CONCLUSION: Canadian compa-
nies have expanded their use of HE data in recent years.
The focus has shifted from preferential internal use (pric-
ing and marketing) to more external purposes such as
provincial and hospital formulary submissions. Health
economic research data also find a place in training
within pharmaceutical companies and in medical educa-
tion.
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OBJECTIVES: The use of formulary system can ensure
high quality and control cost if the formulary decision is
based on appropriate clinical and economic consider-
ations. We explored use of pharmacoeconomic data in
hospitals for formulary decisions. METHODS: Study de-
sign was cross-sectional telephone survey using a struc-
tured survey instrument. Participants were pharmacists
who are P&T committee members of Florida hospitals.
RESULTS: Data were collected from 73 hospitals. Most
hospitals make formulary decisions at the local level
(82%). Thirty-three percent indicate that pharmacoeco-
nomic data is used “all the time” when formulary deci-
sions are made with only six percent stating that it is
rarely or never used. Pharmacoeconomic data is rated by
62% of participants to be “very important” in formulary
decisions. The usual sources of pharmacoeconomic data
listed by participants are in-house data (73%), published
literature (55%), and pharmaceutical industry studies
(15%). When asked to rank order 10 criteria in making
formulary decisions, the mean ratings of participants sug-
gested the following order of importance: Efficacy, Tox-
icity, Side Effects, Acquisition Cost, Costs weighed by
Benefits, Extent of Drug Monitoring, Availability of Oral
Therapy, In-house data, Average Hospital LOS, Avoiding
use of Home Infusion. Most participants reported that
someone with pharmacoeconomic skills is employed by
the hospital (one has a Masters degree, one has residency
training, 31 with practical experience and 15 have infor-
mal training). Based on a pharmacoeconomic case study
comparing a new drug B to a current drug A, most of the
participants would add drug B to the formulary if it is a
new class of drug with no pre-existing resistance, has the
advantage of reduced IV use, or has a consistent reduc-
tion in hospital LOS. CONCLUSIONS: Results of this
study confirms that most hospitals consider pharmaco-
economic data invaluable in formulary decisions.
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OBJECTIVES: This analysis compares the characteristics
and processes of technology assessment (TA) in large
medical groups and HMOs. METHODS: The survey
populations were large medical groups and large HMOs
(at financial risk for lives 100,000). Mail and telephone
questionnaires were implemented. RESULTS: Survey re-
sponse rate among medical groups was 54% (39/73). Re-
sponse rate among HMOs was 43% (41/96). In respond-
ing medical groups, TA involves physicians (100%),
finance staff (85%), and quality improvement staff
(77%). In responding HMOs, medical functions (91%)
and pharmacy functions (83%) participate in TA. Medi-
cal groups most frequently conduct TA when technology
is adopted into clinical practice (88% of respondents)
and use TA to help develop guidelines (84%). HMOs
conduct TA throughout the product lifecycle and use TA
for coverage determinations. Medical groups and HMOs
conduct TA on injectable biotechnology products more
than any other type of drug. 44% of medical group re-
spondents and 90% of HMO respondents seek outside
assistance for TA, with the Agency for Health care Re-
search and Quality (AHRQ) as a leading source for med-
ical groups and private TA vendors as leading sources for
HMOs. Both medical groups and HMOs consider expert
opinion and peer-reviewed journals as the most valuable
information sources. CONCLUSIONS: The need to man-
age legal and financial risk while focusing on clinical
practice and patient care drives TA in medical groups. A
need to define legally defensible benefits drives TA in
HMOs.
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